Amgen Inc. (AMGN)
AMGN Price and Sentiment
AMGN Latest news
Here Are the Highlights From Amgen's Q3 Results
2021-11-11 07:01The big biotech reported only modest sales growth.
Amgen To Present At The 2021 Annual Cowen IO Summit
2021-11-10 16:00THOUSAND OAKS, Calif., Nov. 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 annual Cowen IO Summit at 2:15 p.m.
3 Nasdaq Stocks to Buy and Hold for Years
2021-11-10 12:25There's no question that stocks in the Nasdaq composite index have seen massive gains over the last year and a half. Even after taking a back seat to cyclicals late last year, the index continues to hit new heights.
3 Safe High-Yield Blue-Chips That Can Triple The Market's Returns In The Next 5 Years
2021-11-09 20:14The S&P has posted 63 record closes this year, and is now 29% overvalued. Stocks could potentially keep melting up into Q1 of next year. But just because the market is being stupid doesn't mean you have to be.
Upcoming Ex-Dividend Dates: November 10-22, 2021
2021-11-09 12:47We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.
The Best 9%-25%+ Undervalued Companies Today
2021-11-09 12:34Looking at the market today, it's clear that while some segments and companies suffer from overvaluation, this is far from a universal state. There are massively undervalued investment opportunities, where you essentially get paid to wait for the company to appreciate.
First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia
2021-11-08 16:09THOUSAND OAKS, Calif., Nov. 8, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the HER-MES study, the first and only head-to-head study of Aimovig® (erenumab-aooe), a calcitonin gene-related peptide (CGRP) inhibitor, against topiramate for adult patients with episodic and chronic migraine.
The Near-Perfect Portfolio For The Good Times And Bad
2021-11-06 09:00No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.
Amgen's Product Portfolio Shuffles To Sustain Growth
2021-11-06 04:49Amgen's Product Portfolio Shuffles To Sustain Growth
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
2021-11-06 00:50Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.